WS Audiology looks to new OTC market – but won't disclose plans

As competitors are arming themselves with products designed for the upcoming OTC sales channel in the US, WSA keeps a tight lid on plans. The new market will start out messy, says CEO Eric Bernard, but it will stabilize eventually.

Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR

On Thursday, WS Audiology could present the best quarterly report since the company was founded when Sivantos and Widex merged in 2019.

The company’s future looks bright, according to WSA’s 2021/2022 outlook, which projects a high single-digit organic growth rate and an operating profit of at least EUR 500m in the current financial year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs